Early diagnosis and management of cardiac amyloidosis: A clinical perspective

Bellofatto, Ilaria Anna; Schindler, Thomas H.; Portincasa, Piero; Carbone, Federico; Canepa, Marco; Liberale, Luca; Montecucco, Fabrizio

doi:10.1111/eci.14160

Eur J Clin Investigation

2024

DOI: 10.1111/eci.14160

|View full text |Cite

Early diagnosis and management of cardiac amyloidosis: A clinical perspective

Ilaria Anna Bellofatto,

Thomas H. Schindler,

Piero Portincasa

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 77 publications

(167 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Mechanisms of damage and therapies for cardiac amyloidosis: a role for inflammation?

Bellofatto,

Nikolaou,

Andreadou

et al. 2024

Clin Res Cardiol

View full text Add to dashboard Cite

The term cardiac amyloidosis (CA) refers to the accumulation of extracellular amyloid deposits in the heart because of different conditions often affecting multiple organs including brain, kidney and liver. Notably, cardiac involvement significantly impacts prognosis of amyloidosis, with cardiac biomarkers playing a pivotal role in prognostic stratification. Therapeutic management poses a challenge due to limited response to conventional heart failure therapies, necessitating targeted approaches aimed at preventing, halting or reversing amyloid deposition. Mechanisms underlying organ damage in CA are multifactorial, involving proteotoxicity, oxidative stress, and mechanical interference. While the role of inflammation in CA remains incompletely understood, emerging evidence suggests its potential contribution to disease progression as well as its utility as a therapeutic target. This review reports on the cardiac involvement in systemic amyloidosis, its prognostic role and how to assess it. Current and emerging therapies will be critically discussed underscoring the need for further efforts aiming at elucidating CA pathophysiology. The emerging evidence suggesting the contribution of inflammation to disease progression and its prognostic role will also be reviewed possibly offering insights into novel therapeutic avenues for CA.

show abstract

Mechanisms of damage and therapies for cardiac amyloidosis: a role for inflammation?

Bellofatto,

Nikolaou,

Andreadou

et al. 2024

Clin Res Cardiol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Early diagnosis and management of cardiac amyloidosis: A clinical perspective

Cited by 1 publication

References 77 publications

Mechanisms of damage and therapies for cardiac amyloidosis: a role for inflammation?

Mechanisms of damage and therapies for cardiac amyloidosis: a role for inflammation?

Contact Info

Product

Resources

About